VERTEX PHARMACEUTICALS INC / MA Weighted Avg Shares (Diluted) 2008-2026 | VRTX
What is weighted avg shares (diluted)?
Weighted average shares outstanding (diluted) includes the basic share count plus all potentially dilutive securities such as stock options, warrants, and convertible bonds. It is used as the denominator to calculate diluted earnings per share.
What is VERTEX PHARMACEUTICALS INC / MA's current weighted avg shares (diluted)?
VERTEX PHARMACEUTICALS INC / MA (VRTX) annual weighted avg shares (diluted) for 2025 was 258.0M, a 0.04% increase from 2024. VERTEX PHARMACEUTICALS INC / MA weighted avg shares (diluted) for the quarter ending March 31, 2026 was 256.3M.
What was VERTEX PHARMACEUTICALS INC / MA's weighted avg shares (diluted) in 2024?
VERTEX PHARMACEUTICALS INC / MA annual weighted avg shares (diluted) for 2024 was 257.9M, a 1.00% decline from 2023.
What was VERTEX PHARMACEUTICALS INC / MA's weighted avg shares (diluted) in 2023?
VERTEX PHARMACEUTICALS INC / MA annual weighted avg shares (diluted) for 2023 was 260.5M, a 0.54% increase from 2022.
What is VERTEX PHARMACEUTICALS INC / MA's 5-year weighted avg shares (diluted) CAGR?
VERTEX PHARMACEUTICALS INC / MA weighted avg shares (diluted) grew at a compound annual growth rate (CAGR) of 0.41% from FY2020 to FY2025, going from 263.4M to 258.0M over 5 years.
Year-over-year comparison from 10-K annual reports
| Period | Value | Change | Source |
|---|---|---|---|
| FY2025 | 258.0M | +0.0% | 10-K |
| FY2024 | 257.9M | -1.0% | 10-K |
| FY2023 | 260.5M | +0.5% | 10-K |
| FY2022 | 259.1M | -0.3% | 10-K |
| FY2021 | 259.9M | -1.3% | 10-K |
| FY2020 | 263.4M | +1.0% | 10-K |
| FY2019 | 260.7M | +0.6% | 10-K |
| FY2018 | 259.2M | +2.4% | 10-K |
| FY2017 | 253.2M | +3.5% | 10-K |
| FY2016 | 244.7M | +1.4% | 10-K |
| FY2015 | 241.3M | +2.6% | 10-K |
| FY2014 | 235.3M | +4.6% | 10-K |
| FY2013 | 224.9M | +4.5% | 10-K |
| FY2012 | 215.3M | +3.1% | 10-K |
| FY2011 | 208.8M | +4.2% | 10-K |
| FY2010 | 200.4M | +15.7% | 10-K |
| FY2009 | 173.3M | +23.3% | 10-K |
| FY2008 | 140.6M | - | 10-K |